Compare MSS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | BRTX |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 9.3M |
| IPO Year | 2023 | N/A |
| Metric | MSS | BRTX |
|---|---|---|
| Price | $0.27 | $0.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 307.5K | 60.2K |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $121,477,295.00 | $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | $7.09 | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.96 | 1.70 |
| 52 Week Low | $0.24 | $0.58 |
| 52 Week High | $3.96 | $2.50 |
| Indicator | MSS | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 14.21 |
| Support Level | $0.24 | $1.01 |
| Resistance Level | $0.27 | $1.13 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 47.95 | 3.90 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.